Paris/France—October 5, 2021: Biomillenia and Probiotic Group Luxembourg (PBGL), a leading company in the field of cleaning, hygiene and care solutions, announced today the signing of an R&D collaboration agreement aiming to isolate and characterize novel strains to be used as the next generation active ingredients of eco-friendly disinfectant products.
Biomillenia and Probiotic Group Luxembourg (PBGL), a leading company in the field of cleaning, hygiene and care solutions, announced today the signing of an R&D collaboration agreement aiming
to isolate and characterize novel strains to be used as the next generation active ingredients of eco-friendly disinfectant products.
“We are eager to discover more about Biomillenia’s know how to integrate the greatest strains into our Provilan products. The collaboration aims to quickly and efficiently isolate new bacterial strains exhibiting promising antimicrobial activities. Indeed, in addition to rebalancing the microbiota of our environments, our new range of products in development aim to clean up treated spaces by domesticating the natural defenses of our strains against pathogenic microbes…”
says Martin Schoonbroodt, CCO and co-founder of Probiotic Group.
“Biomillenia has a long-standing expertise in microbiology projects within pharmaceutical industry, agriculture, personal health, and we are delighted to expand now to the new field of hygiene together with Probiotic Group, leader in the development of solutions using live microorganisms as active ingredients. Our state-of-the-art strain banking technologies will deliver microorganisms matching the stringent characteristics required for such applications”
says Dirk Loeffert, Biomillenia President.
About Probiotic Group
Probiotic Group was founded late 2013 in Beiler (Grand Duchy of Luxembourg) to accomplishResearch and Development journey in the field of biotechnology mainly focusing on the human asas animal microbiome. The company develops natural solutions enriched with beneficial and natural bacteria, called probiotics. Our various research projects focus on optimizing the formulations of product ranges with the common objective of improving the microbial balance in our environments.
More and more bacteria infections hit humanity as a result of stronger resistance and over-consumption antibiotics, which makes it clear to all institutions, as well as health experts, that bacterial diseases will, by 2050, be the #1 death cause in the world, far beyond cancer. The issue Probiotic Group has identified is that humanity always focuses on drugs and curative processes to overcome infection cases—built and outdoor environments aren’t taken into consideration—which made it clear to us that the Probiotic Group has a chance to develop sustainable biotechnology-based products which have a positive effect on human & animal health with a zero-carbon footprint.
Further information at www.probiotic-group.com.
Using its proprietary technology platform and its expertise in microfluidics, microbiology, culturomics, molecular biology and bioinformatic Biomillenia isolates strains of beneficial microbes based on their functional traits at speeds and in volumes that to date have not been feasible. Biomillenia also offers its microfluidic platform to leading industry players to develop customized microbiology assays requiring ultrahigh throughput screening capabilities. The company is based in Paris and is a fully owned subsidiary of Design Pharmaceuticals (Boston).
Further information at www.biomillenia.com.